The drug combinations were especially effective on BCR-ABL+ leukemic cells, but they also appeared to have less pronounced but still strong cytotoxic effects on several BCR-ABL- ALL patient cells (Figure 4). Here, ABL1 is linked to acute lymphoblastic leukemia.